Parkinson's Disease Treatment: Past, Present, and Future

Overview

Journal J Neural Transm (Vienna)

Specialties Neurology
Physiology

Date 2020 Mar 16

PMID 32172471

Citations 29

Authors

John D Elsworth

Affiliations

Soon will be listed here.

Abstract

The substantial contributions of Dr. Gerald Stern to past and current treatments for Parkinson's disease patients are reviewed, which form the foundation for an evaluation of future options to control symptoms and halt progression of the disease. These opportunities will depend on a greater understanding of the relative contributions of the environment, genetic and epigenetic influences to disease onset, and promise to emerge as strategies for improving mitochondrial function, halting accumulation of synuclein and neuromelanin, in addition to refinement of stem cell and gene therapies. Such advances will be achieved through deployment of improved models for the disease.

Citing Articles

Corydaline Alleviates 1-Methyl-4-Phenylpyridium (MPP)-Induced Human Neuroblastoma Cell Injury by BAP1-NRF2/HO-1/GPX4 Pathway.

Song Y, Yu C, Wang Y, Bai X, Zhou D Neurochem Res. 2025; 50(2):107.

PMID: 40014251 DOI: 10.1007/s11064-025-04351-9.

The Role of Virtual Reality in Postural Rehabilitation for Patients with Parkinson's Disease: A Scoping Review.

Agostini F, Conti M, Morone G, Iudicelli G, Fisicaro A, Savina A Brain Sci. 2025; 15(1.

PMID: 39851391 PMC: 11764033. DOI: 10.3390/brainsci15010023.

Potential Biomarkers and Treatment of Neuroinflammation in Parkinson's Disease.

Zhao Z, Fu Q, Guo X, He H, Yang G Actas Esp Psiquiatr. 2025; 53(1):181-188.

PMID: 39801407 PMC: 11726199. DOI: 10.62641/aep.v53i1.1779.

Exceeding the Limits with Nutraceuticals: Looking Towards Parkinson's Disease and Frailty.

Montanari M, Mercuri N, Martella G Int J Mol Sci. 2025; 26(1.

PMID: 39795979 PMC: 11719863. DOI: 10.3390/ijms26010122.

The Combined Use of Levodopa/Benserazide and Pramipexole Proves Beneficial for Managing Parkinson's Disease.

Liu Q, Wang H, Lv S, Zhao Y, Zheng Y, Li G Actas Esp Psiquiatr. 2024; 52(6):769-776.

PMID: 39665610 PMC: 11636542. DOI: 10.62641/aep.v52i6.1711.

References

McCaul J, STERN G . Letter: Lithium in Parkinson's disease. Lancet. 1974; 1(7866):1117. DOI: 10.1016/s0140-6736(74)90602-3. View

Zhou J, Bradford H, STERN G . Influence of BDNF on the expression of the dopaminergic phenotype of tissue used for brain transplants. Brain Res Dev Brain Res. 1997; 100(1):43-51. DOI: 10.1016/s0165-3806(97)00019-9. View

Tseng C . Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis. J Clin Med. 2018; 7(10). PMC: 6209987. DOI: 10.3390/jcm7100306. View

Morizane A, Kikuchi T, Hayashi T, Mizuma H, Takara S, Doi H . MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat Commun. 2017; 8(1):385. PMC: 5577234. DOI: 10.1038/s41467-017-00926-5. View

Costa L, de Laat R, Dao K, Pellacani C, Cole T, Furlong C . Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection. Neurotoxicology. 2013; 43:3-9. PMC: 3942372. DOI: 10.1016/j.neuro.2013.08.011. View

Parmar M . Towards stem cell based therapies for Parkinson's disease. Development. 2018; 145(1). DOI: 10.1242/dev.156117. View

Morrow B, Roth R, Redmond Jr D, Diano S, Elsworth J . Susceptibility to a parkinsonian toxin varies during primate development. Exp Neurol. 2012; 235(1):273-81. PMC: 3334464. DOI: 10.1016/j.expneurol.2012.02.005. View

Stern G . The horse that wouldn't run. Pract Neurol. 2012; 12(1):63-7. DOI: 10.1136/practneurol-2011-000113. View

Hunter K, STERN G, Laurence D, Armitage P . Combined treatment of parkinsonism with L-dopa and amantadine. Lancet. 1970; 2(7672):566. DOI: 10.1016/s0140-6736(70)91365-6. View

10.

Bronstein J, Tagliati M, Alterman R, Lozano A, Volkmann J, Stefani A . Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2010; 68(2):165. PMC: 4523130. DOI: 10.1001/archneurol.2010.260. View

11.

Faggiani E, Benazzouz A . Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: From history to the interaction with the monoaminergic systems. Prog Neurobiol. 2016; 151:139-156. DOI: 10.1016/j.pneurobio.2016.07.003. View

12.

Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C . α-Synuclein in Parkinson's disease: causal or bystander?. J Neural Transm (Vienna). 2019; 126(7):815-840. DOI: 10.1007/s00702-019-02025-9. View

13.

Marotta N, Kim S, Krainc D . Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery. Expert Opin Drug Discov. 2020; 15(4):427-441. PMC: 7065944. DOI: 10.1080/17460441.2020.1703671. View

14.

Wolf D, Morey R, Kang E, Ma H, Hayama T, Laurent L . Concise Review: Embryonic Stem Cells Derived by Somatic Cell Nuclear Transfer: A Horse in the Race?. Stem Cells. 2016; 35(1):26-34. DOI: 10.1002/stem.2496. View

15.

Barinapa M . Researchers broaden the attack on Parkinson's disease. Science. 1995; 267(5197):455-6. DOI: 10.1126/science.7824944. View

16.

Christine C, Bankiewicz K, Van Laar A, Richardson R, Ravina B, Kells A . Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. Ann Neurol. 2019; 85(5):704-714. PMC: 6593762. DOI: 10.1002/ana.25450. View

17.

Vila M . Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease. Mov Disord. 2019; 34(10):1440-1451. PMC: 7079126. DOI: 10.1002/mds.27776. View

18.

Carney B, Shah K . Migration and fate of therapeutic stem cells in different brain disease models. Neuroscience. 2011; 197:37-47. PMC: 3589128. DOI: 10.1016/j.neuroscience.2011.08.063. View

19.

Lees A, Shaw K, Kohout L, STERN G, Elsworth J, Sandler M . Deprenyl in Parkinson's disease. Lancet. 1977; 2(8042):791-5. DOI: 10.1016/s0140-6736(77)90725-5. View

20.

Zhang P, Chen Y, Zhang C, Wang Y, Fernandez-Funez P . Genetics of Parkinson's disease and related disorders. J Med Genet. 2017; 55(2):73-80. DOI: 10.1136/jmedgenet-2017-105047. View